CClinicalTrials.gg
Sign In
CompletedNCT01156831Updated Dec 8, 2014

PET-CT Based Radiotherapy in Esophageal Cancer Patients

An observational study in Esophageal Neoplasms, sponsored by Maastricht Radiation Oncology. Completed at 5 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-08.

Sponsored by Maastricht Radiation Oncology · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
115
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients.

Read the detailed description

The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients

02

Conditions studied

  • Esophageal Neoplasms

Keywords

  • Esophageal cancer
  • PET-CT planning
03

In context

Esophageal Neoplasms

1,593 studies on the registry are indexed under Esophageal Neoplasms; 461 are open to participants now.

This study's enrollment of 115 is below the median of 200 across 341 observational studies indexed under Esophageal Neoplasms.

Browse Esophageal Neoplasms studies →

Lead sponsor

Maastricht Radiation Oncology is the lead sponsor of 104 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Primary Care Clinic

Inclusion criteria

  • Histologically proven adenocarcinoma or squamous cell carcinoma of the esophagus
  • Local curable disease able to undergo Chemoradiotherapy.

Exclusion criteria

Exclusion Criteria:

  • Metastasized disease.
  • Previous or concurrent malignancies.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
115 participants (actual)
06

What researchers measure

Primary outcomes

  1. Locoregional control

    Time frame: 2 years and 5 years

Secondary outcomes

  1. Overall Survival

    Time frame: 2 years and 5 years

  2. Disease Free survival

    Time frame: 2 years and 5 years

  3. Tumor regression grade

    Tumor regression grade at time of surgery evaluated by pathologist.

    Time frame: At the time of surgery

07

Study locations

5 sites
  • Atrium Hospital
    Heerlen, Netherlands
  • University Medical Center
    Maastricht, Netherlands
  • St. Laurentius Hospital
    Roermond, Netherlands
  • Maasland Hospital
    Sittard, Netherlands
  • St. Jansgasthuis
    Weert, Netherlands
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01156831
Lead sponsor
Maastricht Radiation Oncology
Responsible party
Sponsor
First posted
Jul 5, 2010
Start date
Nov 2007
Primary completion
May 2011
Completion
May 2013
Last update
Dec 8, 2014

Study contacts

Guido Lammering, MD PhD
principal investigator · Radiation Oncology, Maastro Clinic
Meindert Sosef, MD PhD
principal investigator · Atrium Hospital Heerlen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Esophageal Neoplasms→

Other studies from this sponsor

Maastricht Radiation Oncology

Start the discussion